Speakers

• Ottavio Arancio, MD, PhD Associate Professor, Pathology & Cell Biology, Columbia University Medical Center
• Afia K. Asamoah, Senior Associate, former Special Assistant to the Principal Deputy Commissioner, FDA, Associate, Covington & Burling LLP
• Scott Banta, PhD, Associate Professor, Chemical Engineering, Columbia University
• Michael Barbachyn, PhD. Head of External Science, AstraZeneca
• Richard A. Basile, Chief Executive Officer and Principal, BioPontis Alliance LLC
• Joel Bergman, PhD, Post Doc, University of Illinois at Chicago
• Louis Berneman , Founding Partner, Osage University Partners
• Karen Bernstein, PhD, Co-Founder & Chairman, BioCentury Publications
• David Berry, MD PhD, Partner, Flagship Ventures
• Katherine E. Breedis, CFA, CMT, Senior Director, Global External Research & Development, Eli Lilly & Company
• Renier J. Brentjens, MD, PhD, Medical Oncologist, Memorial Sloan-Kettering Cancer Center
• Anne R. Bresnick, PhD, Professor, Biochemistry, Albert Einstein College of Medicine
• Joseph Brindisi, Business Development Advisor, Prism BioLabs Corporation
• Deborah W. Brooks, Co-Founder and Executive Vice Chairman, The Michael J. Fox Foundation for Parkinson's Research
• Juliane Bubeck-Wardenburg, MD, PhD, Assistant Professor, Department of Microbiology, Department of Pediatrics, University of Chicago
• Anthony Caggiano, MD, PhD, Vice President, Research & Development, Acorda Therapeutics
• Jian Cao, MD, Assistant Professor, Medicine & Pathology, Stony Brook University
• Arnold Caplan, PhD, Professor of Biology, Professor of General Medical Sciences (Oncology), Case Western University
• Arturo Casadevall, PhD, Professor, Chair, Department of Microbiology & Immunology, Department of Medicine, Albert Einstein College of Medicine
• John Cunningham, Senior VP – Regional Market Director & Strategic Ops., Alexandria Real Estate Equities, Inc.
• Min Cho, PhD, Associate Editor, Nature Neuroscience
• James Collins, PhD, Professor of Biomedical Engineering, Boston University, Founding member,  Wyss Institute for Biologically Inspired Engineering, Harvard University
• Robert L. Comis, Professor & Director, Drexel University Clinical Trials Research Center, Philadelphia Coalition Of Cancer Cooperative
• P. Jeffrey Conn, PhD, Lee E. Limbird Professor, Pharamaclogy, Vanderbilt University Medical Center
• Ellen B. Corenswet, Partner, Covington & Burling LLP
• Eric Cottington, PhD, Vice President for Research and Technology Management, Memorial Sloan-Kettering Cancer Center
• Alan Cross, MD Professor, Medicine, University of Maryland School of Medicine
  
• Louis J. DeGennaro, PhD, Chief Mission Officer, Executive Vice President, Leukemia and Lymphoma Society
• Kathleen A. Denis, PhD CLP, Associate Vice President, Office of Technology Transfer, The Rockefeller University
• Sridevi Dhanaraj, PhD, Group Manager, Advanced Technologies and Regenerative Medicine, LLC (ATRM), Johnson & Johnson
• Sheng Ding, PhD, Senior Investigator and Professor, Gladstone Institute of Cardiovascular Disease, Department of Pharmaceutical Chemistry, University of California San Francisco
• Andrew Dorner, PhD, Vice President, Millennium Pharmaceuticals
• Luke C. Düster, Principal, Capital Royalty LP
• Emilia Entcheva, PhD, Associate Professor, Biomedical Engineering, Physiology and Biophysics, Stony Brook University
• Joan Fallon, DC, MSc, Chief Executive Officer, Curemark
• Jian Feng, PhD, Professor, Physiology and Biophysics, State University of New York at Buffalo
• Howard Fillit, MD, Executive Director, Alzheimer's Drug Discovery Foundation
• Jonathan J. Fleming, Managing  General Partner, Oxford Bioscience Partners
• James Foley, PhD, Managing Director, Aqua Partners LLC
• Vance Fowler, MD, MHS, Associate Professor, Department of Medicine, Division of Infectious Diseases Duke University
• Maria C. Freire, PhD, President, Albert and Mary Lasker Foundation
• Les Funtleyder, Health Care Strategist & Portfolio Manager, Miller Tabak Health Care Transformation Fund, Miller Tabak + Co., LLC
• Thomas Gallagher, Chief Patent Counsel, Kadmon Corporation, LLC
• Gunda Georg, PhD, Professor and Head, Department of Medicinal Chemistry, Director, Institute for Therapeutics Discovery & Development, University of Minnesota
• Anthony Giaccio, Partner, Kenyon & Kenyon, LLP
• Colin Goddard, PhD, Executive Chairman & acting CEO, Coferon, Inc.
• Shaun Grady, Vice President, Strategic Partnering and Corporate Business Development, AstraZeneca
• Daniel A. Grande, PhD, Associate Investigator, Director of Orthopaedic Research, Feinstein Institute for Medical Research
• Michael J. Hanewich, Head of Life Sciences East, Life Science Venture Capital, Silicon Valley Bank
• Lizbeth Hedstrom, PhD, Professor of Biology, Brandeis University
• Fritz Henn, PhD, MD, Professor, Neuroscience, Cold Spring Harbor Laboratory
• Joanna Horobin, MD, President & CEO, Syndax Pharmaceuticals
• Gareth John, PhD, Associate Professor, Mount Sinai School of Medicine
• Sudha Kadiyala, PhD, Senior Director, Business Development & Strategic Planning, Advanced Technologies & Regenerative Medicine, LLC, Johnson & Johnson
• Michael Kalos, PhD, Adjunct Associate Professor, Pathology and Laboratory Medicine, Director, Translational and Correlative Studies Laboratory, University of Pennsylvania
• Kristen C. Kosofsky, Managing Director, Horizon Technology Finance
• Demetrios L. Kouzoukas, Of Counsel, Covington & Burling LLP
• Anna D. Kraus, Of Counsel, Covington & Burling LLP
• Barry N. Kreiswirth, PhD, Professor, Director, TB Center, Public Health Research Institute, University of Medicine & Dentistry of New Jersey
• Lauren Krupp, MD, Professor of Neurology and Psychology, Director, National Pediatric MS Center, co-director, MS Comprehensive Care Center, Director, Neuropsychology Research, Stony Brook University Medical Center
• Michael G Kurilla, MD-PhD, Director, Office of BioDefense Research Affairs, Associate Director for BioDefense Product Development, DMID, NIAID, NIH, DHHS
• Leah Lipsich, Executive Director, Regeneron Pharmaceuticals
• Ram May-Ron, Vice President, FreeMind Group
• Jules Mitchel, PhD, President, Target Health Inc.
• Barry Myers, MD,PhD,MBA, Executive-in-Residence, Pappas Ventures
• Scott M. Napolitano, Managing Director, Peter J. Solomon Company
• Ronald Newbold, PhD, Vice President, Strategic Research Partnerships, Pfizer Inc
• Mark Noble, PhD, Professor, Biomedical Genetics, Neurobiology and Anatomy, Neurology, University of Rochester
• Peder S. Olofsson, MD, PhD, Institute Scientist, The Feinstein Institute for Medical Research
• Timothy J. Pelura, PhD, Chairman, President & CEO, Immunome Inc.
• Cary G. Pfeffer, MD, Partner, Third Rock Ventures
• Mark R. Philips, MD, Professor of Medicine, Cell Biology & Pharmacology, NYU School of Medicine, Associate Director for Basic Science, NYU Cancer Institute, Director, MST (MD/PhD) Program
• Thomas A. Picone, PhD. Principal, Partners Unlimited
• Alexander Ploss, PhD, Assistant Professor, The Rockefeller University
• Murali Ramanathan, PhD, Associate Professor, Pharmaceutical Sciences, State University of New York at Buffalo
• Brock C. Reeve, MPhil, MBA, Executive Director, Harvard Stem Cell Institute
• Robert Ring, PhD, Vice President of Translational Research, Autism Speaks
  
• Kent Rogers, MBA, Vice President, Managed Markets, Acorda Therapeutics
• Susan Rohrer, PhD, Senior Director, External Scientific Affairs, Merck & Co., Inc.
• Eric K. Rowinsky, MD, Adjunct Professor, New York University
• Alan J. Russell, PhD, Founding Director, McGowan Institute for Regenerative Medicine
• Charles Ryan, PhD, JD, Sr. Vice President & Chief Intellectual Property Counsel, Forest Laboratories, Inc
• James H. Sabry, MD, Vice President Genentech Partnering, Genentech, Inc.
• Ed Saltzman, President, Defined Health
• Barbara A. Sawitsky, MBA, CLP, Director of Patents & Licensing & Business Development, The New York Blood Center and the Lindsley F. Kimball Research Institute (LFKRI)
• George Scangos, PhD,  CEO, Biogen Idec 
  
• Howard I. Scher, MD, Chief, Genitourinary Oncology Service, Sidney Kimmel Center for Urologic and Prostate Cancers, Memorial Sloan-Kettering Cancer Center
• Sharon E. Semones, Portfolio Consultant, Global External Research and Development, Eli Lilly
• Evonne Sepsis, Managing Director, ECS Advisors
• Braham Shroot, PhD, Chief Executive Officer, Argyle Therapeutics Inc.
• Barbara S. Slusher, PhD, MBA, Chief Scientific Officer, Brain Science Institute, NeuroTranslational Program, Johns Hopkins School of Medicine
• Hans-Willem Snoeck, MD, PhD, Associate Professor, Oncological Sciences, Medicine, Infectious Diseases, Mount Sinai School of Medicine
• E. Jonathan Soderstrom, PhD, Managing Director, Office of Cooperative Research, Yale University
• Hermann Steller, PhD, Strang Professor, Investigator, Howard Hughes Medical Institute, Strang Laboratory of Apoptosis and Cancer Biology, The Rockefeller University
• Lance Stewart PhD, Chief Executive Officer, Emerald BioStructures
• Bruce Stillman, PhD, President, Cold Spring Harbor Laboratory
• Warren J. Strittmatter, MD, Chief, Division of Neurology, Duke Medical Center
• A. Donny Strosberg, PhD, Professor, The Scripps Research Institute-Florida
• Marc Tessier-LaVigne, PhD, President and Professor, Laboratory of Brain Development and Repair, The Rockefeller University
• Charles P. Theuer, MD, PhD, President & CEO, Tracon Pharma
• Lambert van der Walde, Founder, VAN DER WALDE & CO
• William E. Van Nostrand, PhD, Professor, Medicine, Stony Brook University
• George Vradenburg, President, Vradenburg Foundation
• Gordana Vunjak-Novakovic, PhD, Professor, Biomedical Engineering, Columbia University
• Charles A. Weiss, Partner, Kenyon & Kenyon LLP
• Greg Wiederrecht, PhD, Vice President, Worldwide Licensing & External Research, Merck & Co., Inc.
  
• Gunther Winkler, PhD, Board of Trustees, Beth Israel Deaconess Medical Center and member of the Research Oversight Committee
• Barry Wolitzky, PhD,  Executive Director of Strategic Partnering, Immune Tolerance Network
• Daniel Wozniak, PhD, Professor, Infectious Diseases, Ohio State University
• Christopher Yochim, Director, Strategic Planning & Business Development, AstraZeneca
• Michael Young, PhD, Associate Scientist & de Gunzburg Director, Minda de Gunzburg Research Center for Ocular Regeneration, Schepens Eye Research Institute, Associate Professor, Ophthalmology, Harvard Medical School
• Zhenyu Yue, PhD, Associate Professor, Department of Neurology & Neuroscience, Mount Sinai School of Medicine
• Robert A. Zivin, PhD, Senior Director, Corporate Office of Science & Technology, Johnson & Johnson